Updated:
Candel Therapeutics
Candel Therapeutics is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies.
Candel Therapeutics
Candel Therapeutics is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies. Under CEO Paul Peter Tak, the firm has advanced a pipeline centered on two platform technologies: a replication-incompetent adenoviral vector that delivers herpes simplex virus thymidine kinase, and a replication-competent oncolytic adenovirus. The company operates from Needham, Massachusetts. The firm's lead candidate, CAN-2409, targets prostate cancer, non-small cell lung cancer, and other solid tumors in combination with immune checkpoint inhibitors and radiation. A second asset, CAN-3110, is in clinical development for recurrent high-grade glioma. The company's approach couples direct tumor cell death with a systemic immune response, a mechanism that sits adjacent to CAR-T and bispecific antibody programs that dominate immuno-oncology allocations. Candel went public in July 2021 through a business combination with a special purpose acquisition company, a deal structure relatively rare in biotechnology. The transaction brought the firm onto the Nasdaq Global Market under the ticker CADL. The management team includes co-founder and Chief Scientific Officer W. Garrett Nichols, with clinical operations supported by academic collaborations at Brigham and Women's Hospital and Dana-Farber Cancer Institute (per the firm, 2021). The firm is not a family office or a fund manager — it is an operating biotech company with a public listing. For allocators mapping the immuno-oncology landscape, Candel represents a platform technology play rather than a diversified portfolio or pooled investment vehicle. The company's fate is tied entirely to the clinical and regulatory outcomes of its two core assets.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Principals
Paul Peter Tak
President and CEO
Sector focus
Frequently asked questions
Who runs Candel Therapeutics and what is their background?
Paul Peter Tak, M.D., Ph.D., serves as President and CEO. He joined Candel in 2020 after a career that included leadership roles at GlaxoSmithKline, where he served as Senior Vice President and Chief Immunology Officer, and an academic appointment as Professor of Medicine at the University of Amsterdam. His research background is in rheumatology and immunology, which aligns with the company's focus on immune-mediated tumor cell death.
How is Candel Therapeutics funded and what is its capital structure?
Candel Therapeutics is a publicly traded company that listed on the Nasdaq in July 2021 via a SPAC merger with Resilience Acquisition Corp. Prior to going public, the company was venture-backed, with investors including PBM Capital Group and Northpond Ventures. As a public biotech with no approved products, the firm relies on equity financing, milestone payments from partnerships, and public-market raises to fund ongoing clinical trials.
What distinguishes Candel's platform from other immuno-oncology approaches?
Candel's platform uses viral vectors to deliver therapeutic genes directly into tumor cells, aiming for both local tumor destruction and the priming of a systemic immune response. The two platform technologies differ in mechanism: CAN-2409 uses a replication-incompetent adenovirus to express a prodrug-converting enzyme, while CAN-3110 is a replication-competent oncolytic herpes simplex virus. This dual-platform approach is distinct from CAR-T or checkpoint inhibitor monotherapies that dominate the commercial oncology space.
What is the current clinical status of Candel's lead programs?
As of late 2023, CAN-2409 is in Phase 3 development for intermediate-to-high-risk localized prostate cancer, having missed its primary endpoint in a November 2023 readout. The company is also evaluating CAN-2409 in Phase 2 trials for non-small cell lung cancer and pancreatic cancer. CAN-3110 is in a Phase 1/2 study for recurrent high-grade glioma, with data presented at scientific meetings showing signs of biologic activity.
How should allocators evaluate Candel Therapeutics within an investment framework?
Candel Therapeutics is an operating biotech company, not a fund or allocable vehicle. Investors gain exposure through its publicly traded equity (Nasdaq: CADL). For institutional allocators, the firm belongs in a single-stock biotech sleeve — a concentrated bet on viral immunotherapy platforms, with binary risk tied to clinical trial outcomes and FDA regulatory decisions. The company's market capitalization reflects ongoing clinical and financing risk.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: